Undisclosed Bispecific ADC Programs

About Sidewinder Therapeutics

Sidewinder Therapeutics is an early-stage, private biotech developing next-generation precision biologics, primarily bispecific antibody-drug conjugates (ADCs), for oncology and rare diseases. The company is built by a team of serial entrepreneurs and experienced drug developers and has secured a strategic partnership with Lonza's Synaffix for its ADC linker-payload technology. While still in the pre-clinical stage, Sidewinder is positioning itself in the competitive but high-growth ADC therapeutics space with a focus on novel targeting and payload delivery.

Therapeutic Areas